X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
GT-02287 is an orally administered, brain-penetrant small molecule is an allosteric protein modulator that restores the function of the lysosomal protein enzyme glucocerebrosidase (GCase). It is being evaluated for the treatment of GBA1 Parkinson’s Disease.
Lead Product(s): GT-02287
Therapeutic Area: Neurology Product Name: GT-02287
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 27, 2024
Details:
GT-00513 next generation of allosteric small molecule which works by restoring beta-galactosidase function. It is being evaluated for the treatment of GM1-gangliosidosis.
Lead Product(s): GT-00513
Therapeutic Area: Genetic Disease Product Name: GT-00513
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 01, 2023
Details:
Gain intends to use the net proceeds to continue clinical and nonclinical development of its lead product candidate GT-02287 for the treatment of neurodegenerative diseases including GBA1 Parkinson’s disease.
Lead Product(s): GT-02287
Therapeutic Area: Neurology Product Name: GT-02287
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Newbridge Securities Corporation
Deal Size: $4.4 million Upfront Cash: Undisclosed
Deal Type: Public Offering November 24, 2023
Details:
Gain intends to use the net proceeds to continue clinical and nonclinical development of its lead product candidate GT-02287 for the treatment of neurodegenerative diseases including GBA1 Parkinson’s disease.
Lead Product(s): GT-02287
Therapeutic Area: Neurology Product Name: GT-02287
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Newbridge Securities Corporation
Deal Size: $4.4 million Upfront Cash: Undisclosed
Deal Type: Public Offering November 21, 2023
Details:
Gain intends to use the net proceeds to continue clinical and nonclinical development of its lead product candidate GT-02287 for the treatment of neurodegenerative diseases including GBA1 Parkinson’s disease.
Lead Product(s): GT-02287
Therapeutic Area: Neurology Product Name: GT-02287
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Newbridge Securities Corporation
Deal Size: $4.4 million Upfront Cash: Undisclosed
Deal Type: Public Offering November 20, 2023
Details:
GT-02287, an orally administered, brain-penetrant allosteric small molecule modulator of beta-glucocerebrosidase (GCase), Gain’s lead program for GBA1 Parkinson’s disease.
Lead Product(s): GT-02287
Therapeutic Area: Neurology Product Name: GT-02287
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 04, 2023
Details:
GT-02287, an orally administered, brain-penetrant allosteric small molecule modulator of beta-glucocerebrosidase (GCase), Gain’s lead program for GBA1 Parkinson’s disease.
Lead Product(s): GT-02287
Therapeutic Area: Neurology Product Name: GT-02287
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 12, 2023
Details:
The funding will be used to develop GT-02287, an orally administered, brain-penetrant allosteric small molecule modulator of beta-glucocerebrosidase (GCase), Gain’s lead program for GBA1 Parkinson’s disease.
Lead Product(s): GT-02287
Therapeutic Area: Neurology Product Name: GT-02287
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Innosuisse
Deal Size: $2.8 million Upfront Cash: Undisclosed
Deal Type: Funding May 03, 2023
Details:
The funds will advance the development of proprietary allosteric small molecule regulator against AAT Deficiency using computational discovery platform, SEE-Tx which is used to identify unknown allosteric binding sites on protein targets in CNS, oncology and metabolic disease.
Lead Product(s): Undisclosed
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Eurostars
Deal Size: $1.2 million Upfront Cash: Undisclosed
Deal Type: Funding March 21, 2023
Details:
GT-02287 is an allosteric regulator that is designed to increase GCase enzyme activity and decrease neuronal cell death to potentially become the first to develop a treatment for parkinson's disease.
Lead Product(s): GT-02287
Therapeutic Area: Neurology Product Name: GT-02287
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 02, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
